Akari Therapeutics, Plc (AKTX)

BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at the 40 th Annual SITC Meeting being held November 5-9, 2025 in National Harbor, MD.

Data highlights ability of Akari's ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression

BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering the Company's antibody drug conjugate (ADC) platform using Akari's spliceosome payload PH1 for treating cancer by modulating alternative splicing within cancer cells. This patent application represents a new patent family to further extend Akari's proprietary position with respect to the Company's novel payload, PH1 (a novel Thailanstatin analog).

Akari Therapeutics, Plc (NASDAQ:AKTX ) Discusses at Virtual Investor Closing Bell Series Call Company Participants Abizer Gaslightwala - CEO, President & Director Conference Call Participants Jenene Thomas Presentation Jenene Thomas Okay. We are ready to get started.

BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the H.C. Wainwright 27 th Annual Global Investment Conference being held from September 8-10, 2025 in New York, NY.

Live moderated webcast on Thursday, September 4 th at 4:00 PM ET Access the event here BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that it will participate in the Virtual Investor Closing Bell Series on Thursday, September 4, 2025 at 4:00 PM ET.

BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Tuesday, August 19, 2025 at 2:00 PM ET Presenter: Abizer Gaslightwala, President and Chief Executive Officer of Akari Registration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology.

Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari's commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1 Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari's commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1

PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body

BOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari, participated in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference. As part of the event, Mr.

Access the “What This Means” segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced it recently participated in a Virtual Investor “What This Means” segment. For the segment, Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed the Company's recently issued India Patent No.

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms

Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates

BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:00 PM ET.

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.

Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors